Results 21 to 30 of about 4,418 (114)

Immunohistochemical analysis of PD-L1, CD4, CD8, CD20, and PU.1 expression in a dedifferentiated chondrosarcoma: the clinical and prognostic value

Alʹmanah Kliničeskoj Mediciny
Background: Dedifferentiated chondrosarcoma (DDCS) is a rare and extremely aggressive variant of mesenchymal bone tumors, with a biphasic structure represented by the classical chondrosarcoma elements, usually of low or intermediate grade, combined with ...
Olga V. Kovaleva, Irena V. Boulytcheva, Dmitrii V. Rogozhin, Alexei N. Gratchev, Polina L. Prishchep, Nikolay E. Kushlinskii   +5 more
doaj   +1 more source

Monoclonal antibodies targeting CD20 [PDF]

mAbs, 2013
Letter to the Editor: We are commenting on the article by Klein et al. on the functional properties of several anti-CD20 monoclonal antibodies (mAbs) in the January/February 2013 issue of this journal.1 Rituximab, the first monoclonal antibody approved for cancer therapy, has truly revolutionized the treatment of a variety of CD20+ hematological ...
Chang, Chien-Hsing, Rossi, Edmund A., Goldenberg, David M.   +2 more
openaire   +2 more sources

Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma [PDF]

Journal of Pathology and Translational Medicine, 2016
Background: Immunohistochemical demonstration of CD20 in diffuse large B-cell lymphoma (DLBCL) is prerequisite not only for the diagnosis but also for assigning patients to rituximab-containing chemotherapy.
Chang Hwan Choi, Young Hoon Park, Joo Han Lim, Suk Jin Choi, Lucia Kim, In Suh Park, Jee Young Han, Joon Mee Kim, Young Chae Chu   +8 more
doaj   +1 more source

FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy

OncoImmunology, 2018
Diminished overall survival rate of non-Hodgkin lymphoma (NHL) patients treated with a combination regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) has been recently linked to recurrent somatic mutations activating
Beata Pyrzynska, Michal Dwojak, Abdessamad Zerrouqi, Giulia Morlino, Piotr Zapala, Nina Miazek, Agnieszka Zagozdzon, Kamil Bojarczuk, Malgorzata Bobrowicz, Marta Siernicka, Marcin M. Machnicki, Stefania Gobessi, Joanna Barankiewicz, Ewa Lech-Maranda, Dimitar G. Efremov, Przemyslaw Juszczynski, Dinis Calado, Jakub Golab, Magdalena Winiarska   +18 more
doaj   +1 more source

The different predictive effects of the intensity and proportion of CD20 expression on the prognosis of B‐lineage acute lymphocyte leukemia

eJHaem, 2022
The prognostic effects of the CD20 positivity have been studied extensively in B‐lineage acute lymphocyte leukemia (B‐ALL) patients, but the results remain controversial.
Yun Tian, Xiaojiao Wang, Hao Ai, Xiaodong Lyu, Qian Wang, Xudong Wei, Yongping Song, Qingsong Yin   +7 more
doaj   +1 more source

Helicobacter pylori and Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Updated Review of Clinical Outcomes and the Molecular Pathogenesis

Gut and Liver, 2009
In most H. pylori-positive patients, gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphomas regress both endoscopically and histopathologically after H.
doaj   +1 more source

ANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES

Медицинская иммунология, 2014
. Our understanding of the multiple physiological and pathological functions of B-cells continues to expand at a fascinating rate. As pathogenic elements in the development of autoimmune diseases, B-cells have become the focus of new therapeutics.
A. L. Masliansky, V. I. Mazurov, E. G. Zotkin, E. P. Ilivanova, Areg A. Totolian   +4 more
doaj   +1 more source

Anti-CD20 monoclonal antibodies: reviewing a revolution

Human Vaccines & Immunotherapeutics, 2018
Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice.
J. M. L. Casan, J. Wong, M. J. Northcott, S. Opat   +3 more
doaj   +1 more source

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells

Vaccines, 2022
B-cell lymphoma is a group of malignant proliferative diseases originating from lymphoid tissue with different clinical manifestations and biological characteristics.
Yanlong Liu, Kexin Ao, Fuxiang Bao, Yi Cheng, Yanxia Hao, Huimin Zhang, Shan Fu, Jiaqi Xu, Qiyao Wu   +8 more
doaj   +1 more source

CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties

Scientific Reports, 2021
The presence of T cells that are dimly positive for the B cell marker CD20 is well-established in autoimmunity and correlates with disease severity in various diseases.
Martijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, Harm Jan Lourens, Nienke van Rooij, Gerwin Huls, Tom van Meerten, Marco de Bruyn, Edwin Bremer   +8 more
doaj   +1 more source